v3.20.1

Total revenues and other income (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Total revenues and other income |
Summary of Revenues |
|  | Year ended December 31,
|  | 2019 |  | 2018 |  | 2017
|  |  | (Euro, in thousands)
Recognition of non-refundable upfront payments and license fees |  | € | 812,058 |  | € | 196,486 |  | € | 71,971
Milestone payments |  |  | 2,878 |  |  | 73,394 |  |  | 42,950
Reimbursement income |  |  | 19,900 |  |  | 8,722 |  |  | 3,273
Other revenues |  |  | 10,150 |  |  | 10,233 |  |  | 8,893
Total revenues |  | € | 844,985 |  | € | 288,836 |  | € | 127,087
Revenue by collaboration and by category of revenue | The following table summarizes details of revenues for the years ended 31 December 2019 and 2018 by collaboration and by category of revenue: upfront payments and license fees, milestone payments, reimbursement income, and other revenues.
| Over time | Point in time |  | 2019 |  |  | 2018
|  |  |  | (Euro, in |  |  | (Euro, in
|  |  |  | thousands) |  |  | thousands)
Recognition of non-refundable upfront payments and license fees |  |  | € | 812,058 |  | € | 196,486
Gilead collaboration agreement for GLPG1690 |  |  |  | 666,968 |  |  | -
Gilead collaboration agreement for filgotinib (1) |  |  |  | 62,602 |  |  | 96,809
Gilead collaboration agreement for drug discovery platform |  |  |  | 80,918 |  |  | -
AbbVie collaboration agreement for CF |  |  |  | 1,569 |  |  | 52,176
Novartis collaboration agreement for MOR106 |  |  |  | - |  |  | 47,500
Milestone payments |  |  |  | 2,878 |  |  | 73,394
Gilead collaboration agreement for filgotinib (1) |  |  |  | (21,187) |  |  | 27,623
AbbVie collaboration agreement for CF |  |  |  | 24,065 |  |  | 36,771
Servier collaboration agreement for osteoarthritis |  |  |  | - |  |  | 9,000
Reimbursement income |  |  |  | 19,900 |  |  | 8,722
Novartis collaboration agreement for MOR106 |  |  |  | 19,177 |  |  | 7,718
AbbVie collaboration agreement for CF |  |  |  | 723 |  |  | 989
Other reimbursement income |  |  |  | - |  |  | 16
Other revenues |  |  |  | 10,150 |  |  | 10,233
Fee-for-services revenues |  |  |  | 10,084 |  |  | 10,170
Other revenues |  |  |  | 66 |  |  | 63
Total revenues |  |  | € | 844,985 |  | € | 288,836
(1) Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019, included a negative catch-up effect at closing date of €245.9 million, resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.
Summary of allocation of transaction price |
|  |  | (Euro, in thousands)
Allocation of transaction price |  |  |  |
Upfront received |  |  | € | 3,569,815
Impact initial valuation of share subscription |  |  |  | 85,601
|  |  |  | 3,655,416
Less : |  |  |  |
Warrants issuance liabilities |  |  |  |
Warrant A |  |  |  | (43,311)
Initial warrant B |  |  |  | (2,545)
Subsequent warrant B |  |  |  | (16,184)
|  |  |  | 3,593,376
Allocation to performance obligations |  |  |  |
GLPG1690 |  |  |  | 666,967
Filgotinib additional consideration (1) |  |  |  | 641,663
Drug discovery platform (10 years) |  |  | € | 2,284,747
(1)With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component estimated to €44.5 million reflecting the time value of money on the estimated recognition period.
Schedule of revenues | For the years ended December 31, 2018 and 2017 The following table summarizes the revenue recognition of upfront payments, license fees and milestone payments for the years ended December 31, 2018 and 2017, as well as the impact of the adoption of IFRS 15. The revenues recognized for the years ended December 31, 2018 presented under the IFRS 15 standard as well as under the former applicable IAS 18 standard, with a comparison to the year ended December 31, 2017 under the former applicable IAS 18 standard.
|  |  |  |  |  |  |  |  |  |  | IAS 18 |  |  |  |  | IFRS 15 |  | IFRS 15 |  | IAS 18 |  | IAS 18 |  | IFRS 15
Agreement |  | Consideration |  | Consideration |  | Collaboration start date |  | Outstanding balance in deferred income as at December 31, 2017 |  | Deferred income reclassified from equity following adoption of IFRS 15 |  | Outstanding balance in deferred income as at January 1, 2018 |  | Revenue recognized, year ended December 31, 2018 |  | Revenue recognized, year ended December 31, 2018 |  | Revenue recognized, year ended December 31, 2017 |  | Outstanding balance in deferred income as at December 31, 2018
|  | (USD, in thousands) |  | (Euro, in thousands) |  |  |  |  |  |  |  |  |  |  |  |  | (Euro, in thousands) |  |  |  |  |  |  |  |  |
Revenue recognition of considerations received prior to December 31, 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gilead collaboration agreement for filgotinib - Upfront payment |  | $ | 300,000 |  | € | 275,558 |  | January 2016 |  | € | 187,449 |  |  |  |  | € | 187,449 |  | € | 84,806 |  | € | 84,806 |  | € | 62,488 |  | € | 102,643
Gilead collaboration agreement for filgotinib - Subscription agreement (*) |  |  | N.A. |  | € | 39,003 | (*) | January 2016 |  | € | 26,532 |  |  |  |  | € | 26,532 |  | € | 12,004 |  | € | 12,004 |  | € | 8,845 |  | € | 14,528
Servier collaboration agreement for osteoarthritis - License fee |  |  | N.A. |  | € | 6,000 |  | June 2010 |  | € | 5,362 |  | € | (5,362) |  | € | — |  | € | — |  | € | 1,532 |  | € | 638 |  | € | —
AbbVie collaboration agreement for CF - Upfront payments |  | $ | 45,000 |  | € | 34,001 |  | September 2013 |  | € |  |  | € | 14,872 |  | € | 14,872 |  | € | 14,140 |  | € | — |  | € | — |  | € | 732
Total upfront payments and license fees: |  |  |  |  |  |  |  |  |  | € | 219,343 |  | € | 9,510 |  | € | 228,853 |  | € | 110,950 |  | € | 98,342 |  | € | 71,971 |  | € | 117,903
Gilead collaboration agreement for filgotinib - Milestone payments |  | $ | 70,000 |  | € | 64,435 |  | January 2016 |  |  |  |  | € | 43,832 |  | € | 43,832 |  | € | 19,831 |  | € | — |  | € | 9,354 |  | € | 24,001
AbbVie collaboration agreement for CF - Milestone payments |  | $ | 77,500 |  | € | 68,310 |  | September 2013 |  |  |  |  | € | 29,878 |  | € | 29,878 |  | € | 28,406 |  | € | — |  | € | 33,596 |  | € | 1,471
Total milestones: |  |  |  |  |  |  |  |  |  |  |  |  | € | 73,710 |  | € | 73,710 |  | € | 48,237 |  | € | — |  | € | 42,950 |  | € | 25,472
Total : |  |  |  |  |  |  |  |  |  | € | 219,343 |  | € | 83,220 |  | € | 302,563 |  | € | 159,187 |  | € | 98,342 |  | € | 114,921 |  | € | 143,375
Revenue recognition of considerations in the year ended December 31, 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Novartis collaboration agreement for MOR106 - Upfront payment |  |  | N.A. |  | € | 47,500 |  | September 2018 |  |  |  |  |  |  |  |  |  |  | € | 47,500 |  | € | 47,500 |  |  |  |  | € | —
AbbVie collaboration agreement for CF - Upfront payment |  | $ | 45,000 |  | € | 38,874 |  | September 2013 |  |  |  |  |  |  |  |  |  |  | € | 38,037 |  | € | 38,037 |  |  |  |  | € | 837
Total upfront payments and license fees: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 85,537 |  | € | 85,537 |  |  |  |  | € | 837
Gilead collaboration agreement for filgotinib - Milestone payments |  | $ | 15,000 |  | € | 12,418 |  | January 2016 |  |  |  |  |  |  |  |  |  |  | € | 7,793 |  | € | 12,418 |  |  |  |  | € | 4,625
AbbVie collaboration agreement for CF - Milestone payments |  | $ | 10,000 |  | € | 8,548 |  | September 2013 |  |  |  |  |  |  |  |  |  |  | € | 8,364 |  | € | 8,548 |  |  |  |  | € | 184
Servier collaboration agreement for osteoarthritis - Milestone payment |  |  | N.A. |  | € | 9,000 |  | June 2010 |  |  |  |  |  |  |  |  |  |  | € | 9,000 |  | € | 9,000 |  |  |  |  | € | —
Total milestones: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 25,157 |  | € | 29,966 |  |  |  |  | € | 4,809
Total : |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 110,694 |  | € | 115,503 |  |  |  |  | € | 5,646
Grand total : upfront payments and license fees and milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € | 269,881 |  | € | 213,845 |  |  |  |  | € | 149,021
(*) deferred income of €39 million recognized upon signing of the share subscription agreement with Gilead as required under IAS 39
| IFRS 15 |  |  |
| Over time | Point in time | 2018 |  |  |  |  | 2017 |  | Over time | Point in time
|  |  | (Euro, in |  |  |  |  | (Euro, in |  |  |
|  |  | thousands) |  |  |  |  | thousands) |  |
Recognition of non-refundable upfront payments and license fees |  |  | 196,486 |  |  |  | € | 71,971 |  |  |
Gilead collaboration agreement for GLPG1690 |  |  |  |  |  |  |  |  |  |  |
Gilead collaboration agreement for filgotinib |  |  | 96,809 |  |  |  |  | 71,333 |  |  |
Gilead collaboration agreement for drug discovery platform |  |  |  |  |  |  |  |  |  |  |
AbbVie collaboration agreement for CF |  |  | 52,176 |  |  |  |  | - |  |  |
Novartis collaboration agreement for MOR106 |  |  | 47,500 |  |  |  |  | - |  |  | 
Servier collaboration agreement for osteoarthritis |  |  | - |  |  |  |  | 638 |  |  |
Milestone payments |  |  | 73,394 |  |  |  |  | 42,950 |  |  |
Gilead collaboration agreement for filgotinib |  |  | 27,623 |  |  |  |  | 9,354 |  |  | 
AbbVie collaboration agreement for CF |  |  | 36,771 |  |  |  |  | 33,596 |  |  | 
Servier collaboration agreement for osteoarthritis |  |  | 9,000 |  |  |  |  | - |  |  | 
Reimbursement income |  |  | 8,722 |  |  |  |  | 3,273 |  |  |
Novartis collaboration agreement for MOR106 |  |  | 7,718 |  |  |  |  | - |  |  |
AbbVie collaboration agreement for CF |  |  | 989 |  |  |  |  | 453 |  |  | 
Servier collaboration agreement for osteoarthritis |  |  | - |  |  |  |  | 2,816 |  |  | 
Other reimbursement income |  |  | 16 |  |  |  |  | 4 |  |  |
Other revenues |  |  | 10,233 |  |  |  |  | 8,893 |  |  |
Fee-for-services revenues |  |  | 10,170 |  |  |  |  | 8,825 |  |  |
Other revenues |  |  | 63 |  |  |  |  | 68 |  |  |
Total revenues |  |  | 288,836 |  |  |  | € | 127,087 |  |  |
Schedule of other income |
|  | Year ended December 31,
|  | 2019 |  | 2018 |  | 2017
|  |  | (Euro, in thousands)
Grant income |  | € | 6,549 |  | € | 1,609 |  | € | 1,045
R&D incentives |  |  | 43,923 |  |  | 26,912 |  |  | 26,808
Other income |  |  | 433 |  |  | 488 |  |  | 977
Total other income |  | € | 50,905 |  | € | 29,009 |  | € | 28,830

X
- Definition Tabular disclosure of allocation of transaction price under the collaboration agreement. + References No definition available. + Details
Name: | glpg_DisclosureOfAllocationOfTransactionPriceUnderCollaborationAgreementTableTextBlock
Namespace Prefix: | glpg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition n/a + References No definition available. + Details
Name: | glpg_DisclosureOfTotalRevenuesAndOtherIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue by collaboration and by category of revenue. + References No definition available. + Details
Name: | glpg_SummaryOfRevenuesByCollaborationAndByCategoryOfRevenueTableTextBlock
Namespace Prefix: | glpg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the summary of revenues. + References No definition available. + Details
Name: | glpg_SummaryOfRevenuesTableTextBlock
Namespace Prefix: | glpg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_114&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_10_e&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration